FDA is investigating the known risk of hematologic malignancies with serious outcomes following Skysona, including those such as hospitalization, the requirement for allogeneic hematopoietic stem cell transplantation, and death - and is evaluating the need for further regulatory action.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/MgpEBt2
No comments:
Post a Comment